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Abstract Non-communicable diseases (NCDs) have
large economic impact at multiple levels. To system-
atically review the literature investigating the economic
impact of NCDs [including coronary heart disease (CHD),
stroke, type 2 diabetes mellitus (DM), cancer (lung, colon,
cervical and breast), chronic obstructive pulmonary dis-
ease (COPD) and chronic kidney disease (CKD)] on
macro-economic productivity. Systematic search, up to
November 6th 2014, of medical databases (Medline,
Embase and Google Scholar) without language
restrictions. To identify additional publications, we sear-
ched the reference lists of retrieved studies and contacted
authors in the field. Randomized controlled trials, cohort,
case–control, cross-sectional, ecological studies and
modelling studies carried out in adults ([18 years old)
were included. Two independent reviewers performed all
abstract and full text selection. Disagreements were re-
solved through consensus or consulting a third reviewer.
Two independent reviewers extracted data using a pre-
designed data collection form. Main outcome measure
was the impact of the selected NCDs on productivity,
measured in DALYs, productivity costs, and labor market
participation, including unemployment, return to work
and sick leave. From 4542 references, 126 studies met the
inclusion criteria, many of which focused on the impact of
more than one NCD on productivity. Breast cancer was
the most common (n = 45), followed by stroke (n = 31),
COPD (n = 24), colon cancer (n = 24), DM (n = 22),
lung cancer (n = 16), CVD (n = 15), cervical cancer
(n = 7) and CKD (n = 2). Four studies were from the
WHO African Region, 52 from the European Region, 53
from the Region of the Americas and 16 from the Western
Pacific Region, one from the Eastern Mediterranean Re-
gion and none from South East Asia. We found large
regional differences in DALYs attributable to NCDs but
especially for cervical and lung cancer. Productivity
losses in the USA ranged from 88 million US dollars
(USD) for COPD to 20.9 billion USD for colon cancer.
CHD costs the Australian economy 13.2 billion USD per
year. People with DM, COPD and survivors of breast and
especially lung cancer are at a higher risk of reduced labor
market participation. Overall NCDs generate a large im-
pact on macro-economic productivity in most WHO re-
gions irrespective of continent and income. The absolute
global impact in terms of dollars and DALYs remains an
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elusive challenge due to the wide heterogeneity in the
included studies as well as limited information from low-
and middle-income countries.
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Introduction
Non-communicable diseases (NCDs), such as coronary
heart disease (CHD), stroke, chronic obstructive pul-
monary disease (COPD), cancer, type 2 diabetes and
chronic kidney disease (CKD) currently constitute the
number one cause of morbidity and mortality worldwide,
claiming 36 million lives each year (accounting for 63 %
of all adult deaths) [1]. Infectious disease prevention and
control, economic growth, improvements in medical and
scientific knowledge, and health and social systems de-
velopment have all contributed to increased life ex-
pectancy, improved quality of life and increased
likelihood of living to age 60 years and beyond. While
these are notable achievements, together with lifestyle-
related shifts, these epidemiological and socio-demo-
graphic changes also mean that the burden of NCDs will
grow [2].
Productivity is a measure of the efficiency of a person,
business or country in converting inputs into useful out-
puts. The productive age span of a person is from adult-
hood to retirement and ranges from 18 years to around
65 years of age depending on, amongst other things, pro-
fession and country. The measurement of productivity
greatly relies on the output and the economic or social
system context. The focus in this report is macro-economic
productivity loss in the productive age range due to NCDs.
Key macro-economic measures related to the labor market
include: (un-) employment, (loss in) hours worked (in-
cluding full or part-time work status change), presenteeism
(defined as impaired performance while at work), absen-
teeism, disability adjusted life years (DALYs) and pro-
ductivity costs/losses. Key macro-economic outcomes are
reduction in the able workforce, NCD-related health and
welfare expenditure and loss of income earned by the
productive workforce. While both the burden of NCDs and
the socio-economic contexts vary greatly, the impact of the
former on macro-economic outcomes across the global
regions remains unclear.
We aimed to systematically identify and summarize the
literature investigating the impact of six NCDs (CHD,
stroke, COPD cancer, type 2 diabetes and CKD) on macro-
economic productivity and to determine directions for fu-
ture research.
Methods
Search strategy and inclusion criteria
We systematically searched the electronic medical
databases (Medline, Embase and Google Scholar) up to
November 6th, 2014 (date of last search) to identify rele-
vant articles evaluating the macro-economic consequences
of the six selected NCDs, specifically the impact on eco-
nomic productivity of working age citizens. The complete
search strategy is available in ‘‘Appendix 1’’. We defined
the major NCDs of interest as CHD, stroke, chronic ob-
structive lung disease (COPD), type 2 diabetes mellitus
(DM), cancer (lung, colon, breast and cervical) and chronic
kidney disease (CKD). The step-wise inclusion and ex-
clusion procedure is outlined in Fig. 1. Eligible study de-
sign included randomized controlled trials (RCTs), cohort,
case–control, cross-sectional, systematic reviews, meta-
analysis, ecological studies and modeling studies. We in-
cluded studies that estimated the impact of at least one of
the NCDs defined above on at least one of the following
measures of macro-economic productivity: DALYs, eco-
nomic costs related to reduced work productivity, absen-
teeism, presenteeism, (un) employment, (non-) return to
work (RTW) after sickness absence and medical/sick leave.
DALY is also considered as essentially it is an economic
measure of human productive capacity for the affected
individual and when taken together (e.g. all those in a
company, society etc.) forms an economic measure also on
the group level. Only studies involving adults ([18 years
old) were included, without any restriction on language or
date.
Study selection
Two independent reviewers screened the titles and ab-
stracts of the initially identified studies to determine if they
satisfied the selection criteria. Any disagreements were
resolved through discussion and consensus, or by consul-
tation with a third reviewer. In order to ensure that all
retrieved full texts (of the selected abstracts) satisfied the
inclusion criteria appropriately, they were further assessed
by two independent reviewers. We further screened the
reference lists of all retrieved studies to retrieve relevant
articles. Systematic reviews were not included in the data
extraction but a supplementary scan of their reference lists
was performed to identify any additional studies.
Data extraction
A data collection form (DCF) was prepared to extract the
relevant information from the included full texts, including
358 L. Chaker et al.
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study design, World Health Organization (WHO) region,
participants, NCD-related exposure and macro-economic
outcome characteristics. When evaluating economic costs,
US dollars (USD) was used as outcome measure. If a study
reported costs in another currency, the corresponding ex-
change rate to USD as reported by the study itself was
used. However, if an exchange rate was not provided, we
calculated USD applying the conversion rate for the indi-
cated study time-period.
Quality evaluation
To evaluate the quality of the included non-randomized
studies, we applied the Newcastle–Ottawa Scale (NOS) [3].
The NOS scale assesses the quality of articles in three
domains: selection, comparability and exposure. ‘Selec-
tion’ assesses four items and a maximum of one star can be
awarded for each item. ‘Comparability’ awards a max-
imum of two stars to the one item within the category.
Finally, ‘exposure’ includes four items for which one star
can be awarded. A quality score is made for each study by
summing the number of stars awarded, and thus the NOS
scale can have maximum of nine stars. We used this scale
to assess the quality of case–control and cohort studies. For
cross-sectional and descriptive studies, we used an adapted
version of NOS scale (‘‘Appendix 2’’).
Statistical methods
We aimed to pool the results using a random effects model.
If pooled, results would be expressed as pooled relative
risks with 95 % confidence intervals. Pooling possibility
was conditional on the level of heterogeneity between
studies.
Results
General characteristics of the included studies
From 4542 references initially identified, a total of 126
unique studies met the inclusion criteria (Fig. 1; Table 1).
All eligible studies were published between 1984 and
2014. Of the 126 studies identified, 52 were from the
Records identified through 
database searching  
(n = 4449)
Additional records identified 
through other sources  
(n = 121) 
Records after duplicates removed  
(n =4542) 
Records screened 
(n = 4542) 
Records excluded 
(n = 4347) 
Full-text articles 
assessed for eligibility 
(n = 195)
Full-text articles excluded, 
(n = 69) 
Reasons:  
Specific subpopulation: 15 
No details on productivity  
impact of NCD’s: 20 
No or Unclear NCD: 5 
Unspecified NCD: 6 
Review or Book Chapter: 6 
Data extraction not 
possible: 1 
Full-text not obtained: 16 
Studies included in 
qualitative synthesis 
(n = 126) 
Fig. 1 Flowchart of studies for the global impact of non-communicable diseases on macro-economic productivity
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WHO European Region, 53 from the Region of the
Americas (of which all but two were from Canada or the
United States of America [USA]), 16 from the Western
Pacific Region, four were from the WHO African Region
and one from the Eastern Mediterranean Region. We
found no studies from South East Asia. The majority of
the identified studies were observational in design, ana-
lyzed prospectively as well as cross-sectional. Two stud-
ies reported cross-sectional data from an RCT and six
were modeling studies. National or hospital-based disease
registries were often used to select patients, which were in
some cases linked to national socio-economic databases
to extract corresponding employment data. The control
group, if used, was often a sample from the general
population and sometimes sought within the same envi-
ronment of the patients (e.g. same company). Many
studies focused on the impact of more than one NCD on
productivity. Most studies used one measure of produc-
tivity. Of all the published studies including cancers,
cervical cancer was included in seven studies, breast
cancer in 45, colon cancer in 24 and lung cancer in 16.
Stroke was included in a total of 31 studies, COPD in 24,
DM in 22 and CHD was included in 15 studies. Relevant
data on CKD was included in only two of the studies and
two of the studies mention NCDs in general.
Measures of productivity
Measures of productivity impact in the available studies
included DALYs, absenteeism, presenteeism, labor market
(non-) participation, RTW, change in hours worked and
medical/sickness leave. Most studies focused on the direct
impact on the patient but a minority also examined the
impact on caregivers/spouses. Outcomes were quantified
using risks, proportions, odds, dollars, years and days. In
some studies, time-to-event data was analyzed using Cox
proportional-hazards regression. Adjusting for education,
age and employment status was most frequently applied,
although the measurement of education and employment
was not consistently defined, measured or validated. A
small minority of studies reported differences in impact
according to ethnicity. Pooling of outcomes was not pos-
sible due to substantial heterogeneity across and within
NCD groups (I2[ 70 %).
Impact of cardiovascular disease on productivity
Of all DALYs on a population level in Spain (Table 2a),
4.2 % were attributable to CHD [4] with an estimated age-
standardized rate of 4.7 per 1000 persons per year. In
China, DALYs attributable to CHD were estimated to be
8,042,000 for the year 2000 and predicted to more than
double in 2030, rising up to 16,356,000 [5]. In the same
study, the estimated DALY in 2000 was 16.1 per 1000
persons and predicted to be 20.4 in 2030 (estimate not
accounted for age). A study from Kenya estimated the
DALY to be 68 per 100,000 person-years of observation
[6]. CHD-related productivity loss in the USA was esti-
mated to be 8539 USD per person per year (PP/PY), at
10175 USD PP/PY [7] for absenteeism and 2698 USD PP/
PY for indirect work-related loss [8]. Total absenteeism-
related costs in Australia were estimated at 5.69 billion
USD, mortality-related costs at 23 million USD and costs
related to lower employment at 7.5 billion USD [9]. An
estimated 4.7 working days PP/PY were lost in the USA
owing to CHD [10]. Also in the USA, the odds of expe-
riencing limited amount of paid work due to illness were
significantly higher for those with CHD compared to the
control group, with an odds ratio (OR) of 2.91 for women
(95 % CI 2.34–3.61) and 2.34 for men (95 % CI 1.84–2.98)
[11]. In Denmark workforce participation increased with
increasing time from 37 % after 30 days to 65 % after
5 years of diagnosis [12]. In a study conducted in 10
European Union (EU) countries, no difference was found
for the risk of non-participation in the labor force between
those with and without self-reported CHD with an OR of
0.96 (95 % CI 0.66–1.40).
Impact of stroke on productivity
Stroke accounted for 3.5 % of all DALYs reported in
Spain (Table 2b) with a rate of 3.8 per 1000 people [4].
Another study from Spain reports a total count of DALYs
of 418,052 with a higher number of male than for female
(220,005 vs. 198,046) [13]. A study from Kenya reports a
rate of 166 DALYs per 100,000 person-years observed
[6]. In Western Australia, the average annual stroke-at-
tributable DALY count is an estimated 26,315 for men
and 30,918 for women [14]. In Spain, costs after diagnosis
increased over time for caregivers but declined for pa-
tients (14,732 USD in caregivers compared to 2696 USD
among patients after 1 year and 15,621 USD to 1362 USD
after 2 years) [15]. Modeled productivity losses in South
Korea were higher for a severe stroke among men
(537,724 USD) than women (171,157 USD) [16]. A
prospective surveillance study from Tanzania report a
mean costs of productivity loss to be 213 USD [17]. In-
conclusive evidence of the impact of stroke on RTW was
reported. Estimates ranged from 26.7 to 75 % in studies
reporting RTW in stroke patients after 1 year of the event
[18, 19]. In Nigeria, 55 % returned to work at a mean of
19.5 months after stroke. A report from the United
Kingdom (UK) found that 47 % were unemployed 1 year
after stroke [20]. Increased odds to report limited ability
for paid work were found among men (3.86) and women
(2.26) after stroke [11].
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Impact of cervical cancer on productivity
There are strong regional differences in the percentage of
DALYs attributable to cervical cancer (Table 2c) among
women, from 1.6 % (absolute DALYs, 1061 per year) in
New Zealand to 13.4 % (2516 per year) in Brazil [21, 22].
Cervical cancer patients in Argentina reported negative
outcomes after 1 year; 45 % of patients reported reduced
labor market participation, 28 % experienced work inter-
ruption and 5 % changed work [23]. Compared to the
general population, the relative risk (RR) for cervical
cancer survivors in labor force participation was 0.77
(95 % CI 0.67–0.90), 2–3 years after diagnosis in Finland
[24]. In Norway however, no differences were found
5 years from diagnosis with an OR of 0.92 (0.63–1.34)
[25].
Impact of breast cancer on productivity
Of all the DALYs attributable to cancers among women,
27.3 % (17,840 per year) in New Zealand (Table 2d) and
13.4 % (6280 per year) in Brazil are attributable to breast
cancer [21, 22]. Total mortality-related lifetime produc-
tivity loss costs in the USA were estimated to be 5.5 billion
USD [26]. This was differentially distributed between the
two ethnic groups reported, with 71 % (or 3.9 billion USD)
of the costs attributable to white women and 24 % (or 1.3
billion) attributable to black women. Differential RTW and
sick absence rates are also observed comparing black and
white women in the USA; the percentage of white women
returning to work three months after diagnosis was 74.2 %
compared to 59.6 % of black women; the proportion re-
porting sick leave was 25.8 % of white women compared
to 40.4 % of black women [27]. 1 year after primary sur-
gery in Germany, nearly three times as many cancer sur-
vivors had left their job as compared to women in the
control group. [28] Various studies suggest higher unem-
ployment among breast cancer survivors, reported by
around half after 1 year, 72 % after 2 years [29], 43 %
after 6 years and 18 % after 9 years [27, 28, 30–32]. In
contrast, in a study assessing unemployment among the
spouses of breast cancer patients, no differences were
found [33]. Differences between countries in average time
to RTW were also found, from 11.4 months in the
Netherlands [34] and 7.4 months in Canada [35] to only
3 months in Sweden [36]. Percentage of RTW after 1 year
ranged from 54.3 % in a cross-sectional study from France
to 82 % in a prospective study from the USA [37, 38].
Impact of cancer on productivity
In New Zealand, of all the DALYs attributable to cancers,
12.9 % (8431 per year) among women and 13.5 % (8316
per year) among men are attributable to colon cancer
(Table 2e) [22]. In Brazil, these proportions are 9.3 %
among women and 7.5 % among men [21]. In Spain, 2.1 %
of DALY’s overall are attributable to colon cancer [4]. In
Iran the total burden of colorectal cancer in 2008 was 52,534
DALYs and higher for men than for women [39]. In the
USA, annual productivity losses were calculated to be 20.9
billion USD [40], while costs due to absenteeism after
1 year of diagnosis was 4245 USD per patient compared to
the general population [41]. Although the DALY and dollar
costs of colon cancer are undoubtedly large, the evidence for
micro-level labor market indicators including risk and pro-
portions of RTW, sickness absence and employment fol-
lowing diagnosis and treatment is however inconclusive [25,
42–49]. In New Zealand, of all cancer-attributable DALYs,
14.4 % (9334 per year) among women and 15.9 % (9806
per year) among men are attributable to lung cancer
(Table 2f) [22]. In Brazil, lung cancer results in an estimated
10,832 DALYs per year, 9.8 % of all cancer-related DALYs
among women and 24.5 % among men [21]. In Spain,
3.4 % of all DALYs are attributable to lung cancer [4]. Most
of the first year of disease (275 days) is spent in sickness
absence in Sweden [36] and between 33 and 79 % of lung
cancer patients in the USA were unemployed 15 months
after diagnosis [43, 46]. Average time to re-enter the labor
market was 484 days for full-time work and 377 for part-
time work in the Netherlands [50]. The odds of re-entry into
the labor market were significantly lower for lung cancer
than the general population [24, 25, 51].
Impact of COPD on productivity
COPD patients have a higher chance of working fewer
hours, of absenteeism and of poorer work performance
(presenteeism) (Table 2g). [11, 52, 53]. A COPD patient
loses around 8.5 workdays per year due to disease [10, 54].
Between 39 and 50 % of people stopped working due to
the onset of COPD in the Netherlands [55, 56]. COPD-
related productivity losses cost the US economy around 88
million USD or around 482,966 working days per year
[57]. Modeled annual costs of COPD, estimated at 1.47
billion USD [58], are higher in Japan than the USA. The
productivity loss costs PP/PY were somewhat comparable
between Germany, Sweden and the Netherlands (566, 749
and938 USD respectively) [57, 59, 60], but differed four-
fold to estimated costs in Denmark (2816–3819 USD) [61,
62] and more than tenfold to what was estimated (9815
USD) in the USA [63]. In the USA, 8.5 work days are lost
PP/PY on average [10], while COPD patients take an es-
timated 8.6 days of sickness absence in the Netherlands
during a 2 year follow-up period [54]. Also in the
Netherlands, 39 % of COPD patients left the labor force
due to disease onset [55].
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Impact of chronic kidney disease on productivity
Only two studies (Table 2 h) examined the impact of CKD
on productivity. One found that renal dysfunction was in-
dependently associated with labor force non-participation,
with an odds ratio of 7.94 (95 % confidence interval,
1.60–39.43) [64]. The second study, evaluating labor
market participation in CKD patients specifically after
dialysis or transplantation, found that 35 % of these CKD
patients were unemployed [65].
Impact of diabetes mellitus on productivity
In Spain, nearly 2 % of all mortality-related DALYs are at-
tributable to DM [4]. In South Africa, 162,877 DALYs an-
nually are attributable to DM (Table 2i) [4, 66]. A study from
Kenya reports a rate of 364 DALYs per 100,000 observed
person-years [6]. An estimated 7.2 days are lost PP/PY due to
DM in the USA [10] and DM patients have an increased risk
of absenteeism, presenteeism and inability to work [4, 10, 11,
52, 64, 67–69]. Productivity days lost per year due to diabetes
ranged from 3.6 to 7.3 [10, 70]. In the USA, proportion of
productivity loss was large due to premature mortality (49 %)
and presenteeism (44 %) compared to absenteeisim (4 %)
and total productivity related costs were estimated to be
1,962,314 USD [71]. The odds of non-participation of the
labor force for diabetes patients compared to the general
population were slightly higher with borderline significance
in the EU, an OR of 1.38 (95 % CI 0.99–1.93) [69].
Discussion
This systematic review identified 126 studies investigating
the impact of NCDs on productivity. Most studies (96 %)
were from the Western world (North America, Europe or
Asia Pacific), with limited evidence available from Brazil,
South Africa, Kenya, Tanzania, Iran, Japan, South Korea
and Argentina. Macro-economic productivity losses were
measured in percentage and absolute numbers of DALYs
and annual productivity loss costs (in USD). Studies also
estimated productivity losses using labor market indicators
including unemployment, RTW, absenteeism, presen-
teeism, sickness absence and loss in working hours. There
is a clear scarcity in literature concerning the effect of
CKD on productivity, with only two studies both reporting
a substantial impact on productivity [64, 65].
Diversity in the macroeconomic measures
and outcomes
There were considerable global differences in the NCD-
attributable DALY burden, especially the differential
impact of each NCD comparing high-income countries
(HIC) and low- and middle-income countries (LMIC).
Lung and colon cancer account for nearly 30 % of all
cancer-attributable DALYs in men in New Zealand
whereas in Brazil, lung cancer alone accounts for nearly
25 %. Among women in HIC, breast cancer seems to im-
pose a large productivity burden whereas cervical cancer
impacts more dramatically in LMIC [4, 21, 22]. Although
DALYs are a reliable measure and capture both years of
life lost and years spent in ill-health, we found inconsistent
application in the identified studies; some estimated pro-
portions within specific disease groups or of the overall
DALY burden in a country; others estimated absolute
DALY numbers.
Diversity in the macro-economic impact
of the cardiopulmonary diseases
Absolute costs (measured in USD) were estimated for
COPD, CHD, and stroke events [7, 9, 15, 57, 58, 71]. These
studies mainly came from HIC, although two studies, one
from Kenya and one from Tanzania, were also retrieved. In
Australia, absenteeism and lower employment due to CHD
cost 13.2 billion USD annually, as well as an additional 23
million USD in mortality-related costs [9]. Evidence sug-
gests that COPD costs around 88 million USD or nearly
500,000 working days per year in the US compared to 1.47
billion (modeled) in Japan. While annual COPD-related
productivity costs were comparable in Germany, Sweden
and the Netherlands (between 566 and 938 USD), costs
differed fourfold (2816–3819 USD) in Denmark, tenfold
(9815 USD) in the USA [57, 59–63]. In the USA, nearly
half of the annual 1.96 m USD productivity losses due to
DM are attributable to mortality, with 44 % attributable to
presenteeism and just 4 % to absenteeism In South Korea,
modeled productivity losses for a stroke were 68 % higher
among men compared to women [16]. Around half of all
stroke survivors in unemployed after 1 year [20]. In Tan-
zania, productivity losses after 6 months following stroke
were 213 USD on average although these losses were most
acutely experienced by those in higher skill roles [17].
Interestingly, indirect productivity losses were higher
among caregivers than stroke patients themselves and costs
increased for caregivers but declined for patients after 1
and 2 years following a stroke in Spain. COPD patients
experience reduced working hours, unemployment, ab-
senteeism and presenteeism [10, 11, 52–56]. DM patients
also have an increased risk of reduced labor market par-
ticipation [10, 11, 52, 64]. By contrast, other than for ab-
senteeism [10] the evidence for the risk of reduced labor
market participation due to CVD is inconclusive. In Kenya,
68/100,000 person year observed are attributable to CVD
compared to 166/100,000 for stroke and 364/100,000 for
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DM [6]. Although evidence is limited, the higher produc-
tivity impact associated with diseases with a large mor-
bidity was perhaps to be expected; chronic diseases such as
COPD and DM affect people during their productive years
and cannot really be ‘cured’, only managed. The extent to
which employers or societies support and enable NCD
populations to remain members of the productive work-
force will also differentially distribute the impact. The
extent to which secondary or tertiary prevention is possible
will also affect productivity estimates, specifically so for
labor market indicators such as RTW, change in work
status or unemployment.
Diversity in the macroeconomic impact of cancer
Lung cancer survival is associated with reduced labor
market participation through sickness absence, extended
RTW [36, 50] and unemployment [25, 43, 46]. Total
mortality-related lifetime productivity loss due to breast
cancer were an estimated 5.5 billion USD in the USA [26]
and annual productivity losses due to colon cancer costs the
US economy 20.9 billion USD [40].We found inconclusive
evidence of risk of reduced labor market participation
(RTW, sickness absence and unemployment) following
colon cancer diagnosis and treatment [25, 42–46, 48]. The
evidence for breast cancer-related labor market drop-out
shows higher unemployment among survivors 1, 2, 6 and
9 years after diagnosis [29–32]. Evidence from the USA
also suggests ethnicity-patterned differences in sick leave
and unemployment [27]. Along with possible socio-eco-
nomic differences associated with these outcomes [72],
pathophysiological differences may also play a role. Afri-
can-American women have lower incidence of breast
cancer but higher mortality and are also diagnosed in later
stages and with more aggressive types of tumors [73].
However, we are cautious in over interpretation of this
finding as few studies included ethnicity. Geographic dif-
ferences in average months to RTW were observed from
11.4 in the Netherlands [34] to 7.4 in Canada [35] to just
three months in Sweden [36].
Although evidence is limited, the higher productivity
impact associated with diseases with a large morbidity was
perhaps to be expected; chronic diseases such as COPD
and DM affect people during their productive years and
cannot really be ‘cured’, only managed. It is surprising that
half of all productivity losses in the USA attributable to
DM are due to mortality rather than absenteeism and pre-
senteeism. The extent to which employers or societies
support and enable NCD populations to remain members of
the productive workforce will also differentially distribute
the impact both within societies but also comparing more
affluent to less affluent countries. The extent to which
secondary or tertiary prevention is possible will also affect
productivity estimates, specifically so for labor market
indicators such as RTW, change in work status or
unemployment.
Comparison with the previous work
Findings of this systematic review generally concur with
and further extend the previous reviews. This study is a
comprehensive systematic review tackling work-related
burden of six major NCDs using a global perspective and
without language limitation. Two reviewers included and
assessed the studies and references of the included studies
were tracked for any missing evidence. These approaches
ensured that we included most of the relevant articles in our
review. Similar to previous reviews, we found that, due to a
great amount of variation in the studies included, compa-
rability and pooling the studies were not possible. Most of
the previous reviews were performed non-systematically
and previous systematic reviews have included studies only
in English. Previous studies were mainly focused on the
impact of cancers [74–78] on work-related outcomes
(mainly RTW) and often included a mix of cancers without
specifying the type of cancer. Van Muijen and colleagues
[78] reviewed only cohort studies of cancer-related work
outcomes and were focused on English language. Steiner
and colleagues [76] reviewed English publications pub-
lished up until 2003, Breton and colleagues were focused
only on diabetes and Krisch and colleagues focused on
COPD in Germany [79].
Strengths and limitations of the current work
In this systematic review we evaluated the literature con-
cerning the impact on productivity of six top NCDs. These
six were selected based on their dominance in the global
burden of disease and together make a huge contribution to
mortality and morbidity worldwide. Several important is-
sues are out of scope for this work but do merit future
research. First, we did not look into the underlying
mechanisms of what forces people with NCDs in and out of
the labor force, specifically in terms of co-morbidities
(certain NCDs cluster in the same populations) and finan-
cial/social means available at an individual and collective
level. How these mechanisms interact will also be different
according to the level of economic and social development.
For example, children in LMIC are more likely to be forced
into the labor market due to the onset of NCDs in parents
compared to children in HIC and the productive output of
this child cannot replace the loss due to drop out by the
parents. These related topics should be addressed
separately to better understand how to modify and target
these outcomes more specifically. Second, we observed
wide heterogeneity in all domains within the studies
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selected, including study design, methods and sources used
to measure productivity, adjustment for confounders and
analyses. Third, no identified studies quantified the differ-
ential productivity impact by national economic develop-
ment and labor market structure across countries. How
these inter-country macro-economic differences might
mitigate or magnify productivity losses associated with
NCDs is worth further exploration. Fourth, we identified a
crucial gap of relevant information from LMICs—limiting
the relevance of our review most acutely in these settings.
This lack of evidence could reflect differences in disease
burden, in research capacity, in welfare systems and in
epidemiological surveillance. The burden of NCDs is
growing rapidly in LMIC; countries that often lack ca-
pacity in these key areas of support, prevention and
knowledge generation. Further evaluation, therefore, of the
macro-economic impact in the LMIC countries is urgently
needed. Also, many NCDs affect people cumulatively over
time; people may suffer DM, may experience absenteeism/
presenteeism as a result, may reduce work as DM worsens
and may finally drop out of the workforce due a stroke or
CHD, which is related to the DM. Given NCDs are shifting
more and more into chronic conditions, as our under-
standing of treatment and natural history improve, it would
be of great interest to investigate the effects over the life
course rather than using short time horizons such as a year.
This is no mean feat, but could be crucial for developing a
better understanding of the economic impact of NCDs on a
regional, national and international level. Also out of scope
for this review but of interest for future work are the pro-
ductivity-related impact of behavioural risk factors that
contribute to the development of NCDs.
Conclusions
In summary, available studies indicate that the six main
NCDs generate a large impact on macro-economic pro-
ductivity in the WHO regions. However, this evidence is
heterogeneous, of varying quality and not evenly geo-
graphically distributed. Data from LMI countries in eco-
nomic and epidemiological transition are virtually absent.
Further work to reliably quantify the absolute global im-
pact of NCDs on macro-economic productivity and
DALYs is urgently required.
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Nestlé Nutrition (Nestec Ltd.); Metagenics Inc.; and AXA had no role
in design and conduct of the study; collection, management, analysis,
and interpretation of the data; and preparation, review or approval of
the manuscript. Dr. Shanthi Mendis from the WHO and co-author on
this manuscript participated in the interpretation and preparation of
this manuscript. The manuscript was approved by the WHO for
submission.
Conflict of interest With regard to potential conflicts of interest,
there is nothing to disclose. Drs. Chaker, van der Lee, Falla and
Franco had full access to all the data in the study and take respon-
sibility for the integrity of the data and the accuracy of the data
analysis.
Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted
use, distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a
link to the Creative Commons license, and indicate if changes were
made.
Appendix 1: Search strategy up to 6th
of November 2014
(‘non communicable disease’/de OR ‘ischemic heart dis-
ease’/exp OR ‘cerebrovascular accident’/exp OR ‘chronic
obstructive lung disease’/de OR ‘lung cancer’/exp OR
‘colon cancer’/exp OR ‘breast cancer’/exp OR ‘chronic
kidney disease’/de OR ‘non insulin dependent diabetes
mellitus’/de OR ‘uterine cervix cancer’/exp OR (‘non
communicable’ OR noncommunicable OR ((heart OR
cardiac OR cardial OR cardiopath* OR cardiomyopath*
OR coronar* OR myocard*) NEAR/3 (ischem* OR is-
chaem* OR anoxia OR hypoxia)) OR (coronary NEAR/3
(insufficien* OR occlus* OR disease* OR acute OR
atherosclero* OR arteriosclero* OR sclero* OR car-
diosclero* OR constrict* OR vasoconstrict* OR obstruct*
OR stenosis* OR thrombo*)) OR angina* OR ((heart OR
myocard* OR cardiac OR cadial) NEAR/3 infarct*) OR
((cerebrovascul* OR brain OR ‘cerebral vascular’ OR
‘cerebro vascular’) NEAR/3 (accident* OR lesion* OR
attack OR ischem* OR ischaem* OR insult* OR insuffu-
cien* OR arrest* OR apoplex*)) OR cva OR stroke OR
(chronic AND (obstruct* NEAR/3 (lung* OR pulmonar*
OR airway* OR bronch* OR respirat*))) OR ((lung* OR
pulmonar* OR colon* OR colorect* OR breast* OR
mamma*) NEAR/3 (neoplas* OR cancer* OR carcino* OR
adenocarcino* OR metasta* OR sarcom*)) OR (chronic
NEAR/3 (kidney* OR nephropathy* OR renal)) OR
((‘adult onset’ OR ‘type 2’ OR ‘type ii’ OR ‘non-insulin
dependent’ OR ‘noninsulin dependent’ OR ‘insulin inde-
pendent’) NEAR/3 diabet*) OR ((cervix OR cervical)
NEAR/3 (cancer* OR neoplas* OR tumo* OR carcinom*
OR malign*))):ab,ti) AND (adult/exp) AND (‘randomized
controlled trial’/exp OR ‘cohort analysis’/de OR ‘case
control study’/exp OR ‘cross-sectional study’/de OR
‘systematic review’/de OR ‘meta analysis’/de OR ecolo-
gy/exp OR ‘ecosystem health’/exp OR ‘ecosystem
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monitoring’/exp OR model/exp OR ((random* NEAR/3
(trial* OR control*)) OR rct* OR cohort* OR ‘case con-
trol’ OR ‘cross-sectional’ OR (systematic* NEAR/3 re-
view*) OR metaanaly* OR (meta NEXT/1 analy*) OR
ecolog* OR ecosystem* OR model*):ab,ti) NOT ([ani-
mals]/lim NOT [humans]/lim) NOT ([Conference Ab-
stract]/lim OR [Conference Paper]/lim OR [Letter]/lim OR
[Note]/lim OR [Conference Review]/lim OR [Editorial]/
lim OR [Erratum]/lim).
AND (productivity/de OR absenteeism/de OR ‘job
performance’/de OR ‘return to work’/de OR ‘work ca-
pacity’/de OR ‘working time’/de OR ‘medical leave’/de
OR workload/de OR retirement/de OR employment/exp
OR unemployment/de OR (productivit* OR unproductivit*
OR absenteeis* OR presenteeis* OR ((job OR work* OR
profession* OR occupation* OR labour) NEAR/3 (per-
form* OR efficien* OR return* OR back OR capacit* OR
abilit* OR disabilit* OR unab* OR limit* OR impair* OR
loss OR losing OR restrict* OR reduct* OR input*)) OR
(work* NEXT/1 (time OR week* OR day* OR load*)) OR
workweek* OR workday* OR ((medical OR sick) NEXT/1
leave) OR workload* OR ‘time off work’ OR retire* OR
employment* OR employed* OR unemploy* OR daly OR
(‘disability adjusted’ NEXT/2 year*)):ab,ti).
Appendix 2: Newcastle–ottawa quality assessment
scale
Cross-sectional and descriptive studies
Note: A study can be awarded a maximum of one star for
each numbered item within the Selection and Exposure
categories. A maximum of two stars can be given for
Comparability.
Selection
(1) Is definition of NCDs adequate?
(a) Yes, according to a clear and widely used
definition*
(b) Yes, e.g. record linkage or based on self-
reports
(c) No description
(2) Representativeness of the cases
(a) Consecutive or obviously representative series
of cases*
(b) Excluded cases are random*
(c) No description of the excluded cases or
potential for selection biases or not stated
(3) Comparison with a reference group
(a) The results are compared with a reference
from community or with the status of the cases
prior to the disease*
(b) The results are compared with the results from
other patients
(c) No description/no comparison available
(4) Definition of reference
(a) Individuals with no NCD or sample from
general population or the same individuals
before NCD suffering*
(b) Non community comparator is described
(c) No description of source
Comparability
(1) Comparability of the results on the basis of the de-
sign or analysis
(a) The results are described in age and sex sub
groups (sex is not applicable for female
diseases)*
(b) The results are additionally adjusted for/
described in different socioeconomic factors
or disease related confounders*
Exposure (costs, productivity, households)
(1) Ascertainment of exposure
(a) Secure record (e.g. surgical records, hospital
records, and administrative records,
national…)*
(b) Structured interview where blind to case/con-
trol status*
(c) Interview not blinded to case/control status
(d) Written self-report or medical record only
(e) No description




(c) No comparator group exist
(3) Non-response rate
(a) All participants included or same rate for both
groups or respondents and non-respondents
have the same characteristics*
(b) Non respondents described
(c) Rate different and no designation
(d) Response rate not described
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